TMEM231: A Transmembrane Protein Target for Drug Development and Cancer Treatment

Target Name: TMEM231

NCBI ID: G79583

TMEM231

TMEM231: A Transmembrane Protein Target for Drug Development and Cancer Treatment

TMEM231, also known as transmembrane protein 231, is a gene that encodes a protein located at the cell membrane that plays a crucial role in various cellular processes.TMEM231 has been identified as a potential drug target and biomarker for various diseases, including cancer.This article will provide an overview of TMEM231, its potential drug target status, and its potential as a biomarker for cancer diagnosis and treatment.

Overview of TMEM231

TMEM231 is a 21-kDa transmembrane protein that is expressed in various tissues, including brain, heart, liver, and cancer cells. It is characterized by a N-terminus that is involved in protein-protein interactions and a C-terminus that is involved in cell surface carbohydrate interactions.TMEM231 is involved in various cellular processes, including cell signaling, cell adhesion, and cell migration.

Potential Drug Target

TMEM231 has been identified as a potential drug target due to its unique structure and its involvement in various cellular processes.TMEM231 has been shown to play a role in various signaling pathways, including the TGF-β pathway, which is involved in cell signaling and growth. TMEM231 has been shown to interact with the protein SMAD, which is a key regulator of the TGF-β pathway.

In addition to its involvement in the TGF-β pathway, TMEM231 has also been shown to play a role in cell adhesion and migration. TMEM231 has been shown to interact with the protein vimentin, which is involved in cell adhesion, and it has been shown to be involved in the migration of cancer cells.

Potential as a Biomarker

TMEM231 has also been identified as a potential biomarker for cancer diagnosis and treatment. TMEM231 has been shown to be expressed in various types of cancer, including breast, ovarian, and prostate cancer. It has also been shown to be involved in the development of various types of cancer, including neuroendocrine and neuroimaging tumors.

In addition to its potential as a drug target, TMEM231 has also been shown to be a potential biomarker for cancer diagnosis and treatment. It has been shown to be involved in the development and progression of various types of cancer, and it has been shown to be expressed in the blood vessels of cancer cells.

Conclusion

TMEM231 is a transmembrane protein that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and involvement in various cellular processes make it an attractive target for drug development.TMEM231 has also been shown to be involved in the development and progression of various types of cancer, making it a potential biomarker for cancer diagnosis and treatment. Further research is needed to fully understand the potential of TMEM231 as a drug target and biomarker for cancer.

Protein Name: Transmembrane Protein 231

Functions: Transmembrane component of the tectonic-like complex, a complex localized at the transition zone of primary cilia and acting as a barrier that prevents diffusion of transmembrane proteins between the cilia and plasma membranes. Required for ciliogenesis and sonic hedgehog/SHH signaling (By similarity)

The "TMEM231 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM231 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets